Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises

Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises

Ovarian cancer is the deadliest gynecological cancer, the high-grade serous ovarian carcinoma (HGSC) being its most common and most aggressive form. Despite the latest therapeutical advancements following the introduction of vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis...

Full description

Bibliographic Details
Main Authors: Aikaterini Skorda, Marie Lund Bay, Sampsa Hautaniemi, Alexandra Lahtinen, Tuula Kallunki
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
clinical trials
high-grade serous ovarian carcinoma
kinase inhibitor
patient-derived tumor organoids
patient-derived xenografts
personalized medicine
Online Access:https://www.mdpi.com/2072-6694/14/24/6257

Internet

https://www.mdpi.com/2072-6694/14/24/6257

Similar Items